Test whether under GLP1R antagonist or Glp1r LOF that abolishes GLP1R-class neuroprotection / cognition attribution, Exendin-4 still retains neuroprotective or cognitive phenotype
Exendin-4 is framed as supporting neuroprotection and cognition through GLP1R-class attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual Exendin-4 neuroprotection or cognition under a GLP1R antagonist or Glp1r LOF that abolishes GLP1R-class neuroprotection / cognition attribution still requires a path beyond GLP1R-class attribution.
Claim
On a matched rodent cognition / neuroprotection panel (During/Perry/McClean-class) ± Exendin-4 ± GLP1R antagonist (exendin-9-39) or Glp1r genetic LOF titrated so the block abolishes GLP1R-class neuroprotection / cognition attribution, plus neuroprotective or cognitive endpoint: under that GLP1R-abolish condition, residual Exendin-4 neuroprotective / cognitive phenotype remains ≥50% of the Exendin-4 without-GLP1R-abolish arm on the same panel (named comparator = Exendin-4 without-GLP1R-abolish arm under matched panel) — assumption-kill / glp1r-insufficiency.
Why it matters
During maps Glp1r as necessary for learning and kainate neuroprotection; Perry / McClean map Exendin-4 and liraglutide neuroprotection / AD cognition phenotypes; Serre maps Exendin-(9-39) as a murine GLP-1R inverse-agonist tool. P24 asks whether residual Exendin-4 neuroprotection / cognition under a GLP1R antagonist or Glp1r LOF that abolishes GLP1R-class attribution still requires a path beyond GLP1R-class attribution — glp1r-insufficiency assumption-kill. Distinct from P15 (BPC residual-FBXO22), P16 (LKKTETQ-Cc), P17 (MOTS-c/folate), P18 (SS-31/ROS-scavenger), P19 (ARA290/IRR), P20 (Semax/TrkB; Exendin-4≠Semax; GLP1R≠TrkB), P21 (Selank/GABA; Exendin-4≠Selank; GLP1R≠GABA), P22 (Dihexa/c-Met; Exendin-4≠Dihexa; GLP1R≠c-Met), and P23 (oxytocin/OXTR; Exendin-4≠oxytocin; GLP1R≠OXTR); NOT FOXO4×LOF; skip-list unused; orthosteric_drift=false. Soft-claims: discussion — matched residual-under-GLP1R-abolish H2H UNKNOWN; PRIOR_ART PARTIAL (necessity AGAINST residual); soft-complete empty ≠ novelty / ≠ failure; P1–P23 ≠ proof.
Mechanism sketch
glp1r-insufficiency assumption-kill: During shows Glp1r LOF learning deficit and enhanced kainate neuronal injury with agonist benefit through GLP-1R LITERATURE — necessity AGAINST residual; Perry shows Exendin-4 excitotoxic neuroprotection phenotype LITERATURE (no residual-under-abolish arm); McClean shows liraglutide AD cognition phenotype LITERATURE (class phenotype; not Ex4 residual under abolish); Serre shows Exendin-(9-39) inverse agonist at murine GLP-1R LITERATURE (tool prior) — none score residual Exendin-4 under a GLP1R antagonist / Glp1r LOF that abolishes GLP1R-class neuroprotection / cognition attribution on the same panel. Promoted Jia/Gong (PMID 26546042; out of public prior_art ≤4) shows exenatide MCAO neuroprotection completely blocked by exendin (9-39); Zhang (PMID 37595875) shows Exendin-4 CA1 excitation completely blocked by exendin(9-39); Basalay (PMID 31721014) shows semaglutide neuroprotection abolished by exendin(9-39) — stronger necessity H2H AGAINST residual; not residual-positive. GLP1R-class neuroprotection / cognition framing is the class PRIOR under kill — PRIOR necessity / phenotype ≠ matched residual-positive H2H under GLP1R-abolish. P24 scores residual neuroprotection / cognition under GLP1R antagonist or Glp1r LOF that first abolishes GLP1R-class attribution, on the same panel ± Exendin-4 ± GLP1R-abolish (prefer cell / slice / block-QC with exendin-9-39 or Glp1r ablation before new animal During/Perry/McClean-class cognition / neuroprotection panels; still name the in vivo panel as primary kill path). Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; NOT P17 MOTS-c residual under folate repletion; NOT P18 SS-31 residual under matched ROS-scavenger; NOT P19 ARA290 residual under hematopoietic-matched EPO; NOT P20 Semax residual under TrkB antagonist / BDNF neutralize (Exendin-4 ≠ Semax; GLP1R ≠ TrkB); NOT P21 Selank residual under GABA-A/BDZ match (Exendin-4 ≠ Selank; GLP1R ≠ GABA); NOT P22 Dihexa residual under HGF/c-Met block (Exendin-4 ≠ Dihexa; GLP1R ≠ c-Met); NOT P23 oxytocin residual under OXTR antagonist / Oxtr LOF (Exendin-4 ≠ oxytocin; GLP1R ≠ OXTR). Soft-complete empty ≠ novelty / ≠ failure.
Prior art
- PMID 12925848 / DOI 10.1038/nm919 — During: Glp1r-deficient mice learning deficit restored by hippocampal Glp1r gene transfer; enhanced kainate seizure severity / neuronal injury; agonist learning/neuroprotection through GLP-1R — necessity AGAINST residual; Glp1r gene-transfer rescue ≠ Exendin-4 residual under GLP1R abolish.
- PMID 12183643 / DOI 10.1124/jpet.102.037481 — Perry: GLP-1 and Exendin-4 protect cultured rat hippocampal neurons against glutamate-induced apoptosis; reduce ibotenic acid cholinergic depletion in vivo — Exendin-4 neuroprotection phenotype PRIOR (WT receptor context; no Ex9-39 / Glp1r-/- residual arm).
- PMID 21525299 / DOI 10.1523/JNEUROSCI.0529-11.2011 / PMC6622662 — McClean: liraglutide prevents memory impairments (object recognition / water maze), synapse loss, plaque pathology in APP/PS1 AD mice — GLP1R-class cognition/neurodegeneration phenotype PRIOR (liraglutide ≠ Exendin-4 residual under abolish).
- PMID 9794451 / DOI 10.1210/endo.139.11.6295 — Serre: Exendin-(9-39) inverse agonist at murine GLP-1R; lowers basal cAMP / impairs GSIS in βTC-Tet — antagonist/inverse-agonist TOOL PRIOR (not CNS residual H2H).
Baseline claimed
Under GLP1R antagonist (exendin-9-39) or Glp1r genetic LOF that abolishes GLP1R-class neuroprotection / cognition attribution, Exendin-4 still retains neuroprotective or cognitive phenotype on the same panel — or During/Perry/McClean/Serre necessity / phenotype / tool / Jia-Gong Ex9-39 block / Zhang CA1 block / Basalay semaglutide abolish / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P17 MOTS-c/folate / P18 SS-31/ROS / P19 ARA290/IRR / P20 Semax/TrkB / P21 Selank/GABA / P22 Dihexa/c-Met / P23 oxytocin/OXTR / P1–P23 already settle residual-under-GLP1R-abolish.
Baseline measured
During Glp1r LOF learning deficit + enhanced kainate injury LITERATURE (PMID 12925848; necessity AGAINST residual; Glp1r gene-transfer rescue ≠ Ex4 residual under abolish). Perry Exendin-4 excitotoxic neuroprotection LITERATURE (PMID 12183643; phenotype without Ex9-39 / Glp1r-/- residual arm). McClean liraglutide AD cognition LITERATURE (PMID 21525299; class phenotype ≠ Ex4 residual under abolish). Serre Exendin-(9-39) murine GLP-1R inverse agonist LITERATURE (PMID 9794451; tool ≠ CNS residual H2H). Promoted Jia/Gong exenatide MCAO NP completely blocked by exendin (9-39) LITERATURE (PMID 26546042; out of public prior_art ≤4; necessity H2H AGAINST residual). Promoted Zhang Exendin-4 CA1 excitation completely blocked by exendin(9-39) LITERATURE (PMID 37595875; out of public prior_art ≤4; necessity H2H AGAINST residual). Promoted Basalay semaglutide NP abolished by exendin(9-39) LITERATURE (PMID 31721014; out of public prior_art ≤4; class necessity AGAINST residual). Matched residual-positive Exendin-4 neuroprotection / cognition under GLP1R antagonist / Glp1r LOF that abolishes GLP1R-class attribution on same panel UNKNOWN (soft-complete Q_resid NON-MATCH / Q_resid_tight NON-MATCH / Q_block_ex4 necessity-leaning / Q_necess_h2h necessity AGAINST / Q_resid_persist NON-MATCH residual-positive cognition/NP / Q_P20 review NON-MATCH Exendin-4≠Semax GLP1R≠TrkB / Q_P21 GABA adjacent NON-MATCH Exendin-4≠Selank GLP1R≠GABA / Q_P22 islet-ADSC NON-MATCH Exendin-4≠Dihexa GLP1R≠c-Met / Q_P23 adjacent NON-MATCH Exendin-4≠oxytocin GLP1R≠OXTR / FOXO4∩Exendin-4=0 / BPC∩Exendin-4=0 / P15–P19 drift empty). Residual ≥50% of Exendin-4 without-GLP1R-abolish arm under GLP1R-abolish condition PREDICTION (author-chosen; not invented observed effect). P15 ≠ P24; P16 ≠ P24; P17 ≠ P24; P18 ≠ P24; P19 ≠ P24; P20 ≠ P24; P21 ≠ P24; P22 ≠ P24; P23 ≠ P24; P1–P23 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF. Review 41004910 ≠ experimental anchor.
Actionable limitations
- Do not treat P1–P23 as proving P24 — During/Perry/McClean/Serre necessity / phenotype / tool priors are not a residual-under-GLP1R-abolish H2H; Jia/Gong / Zhang / Basalay Ex9-39 blocks lean AGAINST residual; soft-complete empty ≠ demonstrated residual phenotype; do not invent residual when UNKNOWN; do not treat necessity as residual-positive.
- Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS-scavenger, P19 ARA290/IRR, P20 Semax/TrkB (Exendin-4≠Semax; GLP1R≠TrkB), P21 Selank/GABA (Exendin-4≠Selank; GLP1R≠GABA), P22 Dihexa/c-Met (Exendin-4≠Dihexa; GLP1R≠c-Met), or P23 oxytocin/OXTR (Exendin-4≠oxytocin; GLP1R≠OXTR); orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or Selank/GABA/BDZ or Dihexa/HGF/c-Met or oxytocin/OXTR; NOT FOXO4×LOF (SERIES_FROZEN).
- During/Perry/McClean lack an Exendin-4 residual arm under GLP1R-abolish on the same panel; abolish-fail (GLP1R-class attribution not abolished) / Exendin-4-alone-null / underpowered strata / assay-mismatch leave the test inconclusive rather than refuted; do not misread Glp1r gene-transfer rescue (12925848) as Exendin-4 residual under GLP1R abolish; prefer cell/slice/block-QC before new animal; no dosing; reviews ≠ experimental anchors.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| During_Glp1r_LOF_learning_neuroprotection_necessity | LITERATURE | Glp1r-deficient mice; hippocampal Glp1r gene transfer; kainate seizure / neuronal injury; GLP-1 / [Ser(2)]exendin(1-9) learning (During 2003 Nat Med) | Glp1r-deficient mice learning deficit restored by hippocampal Glp1r gene transfer; enhanced kainate seizure severity / neuronal injury; agonist learning/neuroprotection through GLP-1R LITERATURE (PMID 12925848 / DOI 10.1038/nm919) — necessity AGAINST residual; Glp1r gene-transfer rescue ≠ Exendin-4 residual under GLP1R abolish |
| Perry_Exendin4_excitotoxic_neuroprotection_phenotype | LITERATURE | cultured rat hippocampal neurons glutamate apoptosis; ibotenic acid cholinergic depletion in vivo ± GLP-1 / Exendin-4 (Perry 2002 JPET) | GLP-1 and Exendin-4 completely protect cultured rat hippocampal neurons against glutamate-induced apoptosis; reduce ibotenic acid cholinergic depletion in vivo LITERATURE (PMID 12183643 / DOI 10.1124/jpet.102.037481) — Exendin-4 neuroprotection phenotype PRIOR; no Ex9-39 / Glp1r-/- residual arm |
| McClean_liraglutide_AD_cognition_phenotype | LITERATURE | APP/PS1 AD mice; object recognition / water maze; synapse loss; plaque pathology ± liraglutide (McClean 2011 J Neurosci) | liraglutide prevents memory impairments, synapse loss, plaque pathology in APP/PS1 AD mice LITERATURE (PMID 21525299 / DOI 10.1523/JNEUROSCI.0529-11.2011 / PMC6622662) — GLP1R-class cognition phenotype PRIOR; liraglutide ≠ Exendin-4 residual under abolish |
| Serre_Exendin9_39_murine_GLP1R_inverse_agonist_tool | LITERATURE | Exendin-(9-39) at murine GLP-1R; basal cAMP; GSIS in βTC-Tet (Serre 1998 Endocrinology) | Exendin-(9-39) inverse agonist at murine GLP-1R; lowers basal cAMP / impairs GSIS LITERATURE (PMID 9794451 / DOI 10.1210/endo.139.11.6295) — antagonist/inverse-agonist TOOL PRIOR; not CNS residual H2H |
| matched_residual_Exendin4_under_GLP1R_abolish_H2H | UNKNOWN | Same cognition / neuroprotection panel ± Exendin-4 ± GLP1R antagonist (exendin-9-39) or Glp1r genetic LOF — block titrated to abolish GLP1R-class neuroprotection / cognition attribution, plus neuroprotective or cognitive endpoint | dedicated residual-positive Exendin-4 neuroprotective / cognitive phenotype under GLP1R antagonist / Glp1r LOF that abolishes GLP1R-class attribution not found (soft-complete Q_resid NON-MATCH / Q_resid_tight NON-MATCH / Q_block_ex4 necessity-leaning / Q_necess_h2h necessity AGAINST / Q_resid_persist NON-MATCH residual-positive cognition/NP / Q_P20 NON-MATCH / Q_P21 NON-MATCH / Q_P22 NON-MATCH / Q_P23 NON-MATCH / FOXO4∩Exendin-4=0 / BPC∩Exendin-4=0 / P15–P19 drift empty) — UNKNOWN + missing_search; do not invent residual; do not treat necessity as residual-positive |
| residual_Exendin4_neuroprotection_cognition_ge50pct_of_Exendin4_without_GLP1R_abolish | PREDICTION | Pre-registered matched rodent cognition / neuroprotection panel (During/Perry/McClean-class) ± Exendin-4 ± GLP1R antagonist (exendin-9-39) or Glp1r genetic LOF; GLP1R-abolish condition must abolish GLP1R-class neuroprotection / cognition attribution first, then score residual Exendin-4 neuroprotection / cognition vs Exendin-4 without-GLP1R-abolish arm under matched panel (prefer cell/slice/block-QC before new animal; in vivo panel remains primary kill path) | under GLP1R antagonist or Glp1r LOF that abolishes GLP1R-class neuroprotection / cognition attribution, residual Exendin-4 neuroprotective / cognitive phenotype ≥50% of the Exendin-4 without-GLP1R-abolish arm on the same panel (named comparator = Exendin-4 without-GLP1R-abolish arm under matched panel); α/N pre-specified — author-chosen PREDICTION; do not invent observed % / KD / dosing |
| competing_abolish_fail_or_Ex4_alone_null_or_underpowered_or_assay_mismatch_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual is only abolish-fail (GLP1R-class attribution not abolished), Exendin-4-alone-null, underpowered strata, or assay-mismatch | abolish-fail / Exendin-4-alone-null / underpowered / assay-mismatch allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove matched cognition / neuroprotection panel ± Exendin-4 ± GLP1R antagonist or Glp1r LOF under GLP1R-abolish that first abolishes GLP1R-class neuroprotection / cognition attribution, then scores residual Exendin-4 neuroprotection / cognition: Without the GLP1R-abolish × residual H2H, separate During necessity LITERATURE, Perry Exendin-4 phenotype LITERATURE, McClean liraglutide phenotype LITERATURE, and Serre Ex9-39 tool LITERATURE cannot show glp1r-insufficiency of residual Exendin-4 under GLP1R-abolish.
- remove GLP1R-abolish gate plus Exendin-4 without-GLP1R-abolish arm as the named residual comparator (vs During/Perry/McClean/Serre necessity-alone / phenotype-alone / tool-alone / Jia-Gong/Zhang/Basalay Ex9-39 block-alone): Without the GLP1R-abolish gate and Exendin-4 without-abolish comparator under the same block condition, the card collapses into During/Perry/McClean/Serre necessity / phenotype / tool prior or generic GLP1R-class framing and loses glp1r-insufficiency contrast.
- remove P15≠P24 + P16≠P24 + P17≠P24 + P18≠P24 + P19≠P24 + P20≠P24 + P21≠P24 + P22≠P24 + P23≠P24 + P1–P23≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF + do-not-invent-residual-when-UNKNOWN + do-not-treat-necessity-as-residual-positive discipline: Treating P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS, P19 ARA290/IRR, P20 Semax/TrkB, P21 Selank/GABA, P22 Dihexa/c-Met, P23 oxytocin/OXTR, empty PubMed, During/Perry/McClean/Serre alone as residual-positive, Jia/Gong/Zhang/Basalay necessity as residual-positive, or FOXO4/BPC framing as already deciding residual-under-GLP1R-abolish would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered matched rodent cognition / neuroprotection panel (During/Perry/McClean-class) ± Exendin-4 ± GLP1R antagonist (exendin-9-39) or Glp1r genetic LOF where GLP1R-abolish abolishes GLP1R-class neuroprotection / cognition attribution, residual Exendin-4 neuroprotective / cognitive phenotype is <50% of the Exendin-4 without-GLP1R-abolish arm under that same condition — so GLP1R-class-attribution framing survives and glp1r-insufficiency residual fails — when abolish-fail, Exendin-4-alone-null, underpowered strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock one matched rodent cognition / neuroprotection panel (During/Perry/McClean-class) ± Exendin-4 ± GLP1R antagonist (exendin-9-39) or Glp1r genetic LOF with block QC that abolishes GLP1R-class neuroprotection / cognition attribution, neuroprotective / cognitive readout, and ≥50%-of-Exendin-4-without-GLP1R-abolish residual gate before claiming residual under GLP1R abolish; prefer cell / slice / block-QC with exendin-9-39 or Glp1r ablation before new animal cognition / neuroprotection panels (in vivo panel remains primary kill path); do not treat P15 or P16 or P17 or P18 or P19 or P20 or P21 or P22 or P23 or P1–P23 as proof; do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or Selank/GABA/BDZ or Dihexa/HGF/c-Met or oxytocin/OXTR; do not invent residual when UNKNOWN; do not treat necessity as residual-positive; do not misread Glp1r gene-transfer rescue (12925848) as Exendin-4 residual under GLP1R abolish; no dosing; NOT FOXO4×LOF.
Cheap IP
kill_cost_tier=1 · time_to_refute=4w · ip_class=glp1r-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=During Glp1r learning/neuroprotection necessity AGAINST residual; Perry Exendin-4 excitotoxic neuroprotection phenotype; McClean liraglutide AD cognition phenotype; Serre Exendin-(9-39) murine GLP-1R inverse agonist tool; Jia/Gong exenatide NP blocked by Ex9-39 (promoted necessity; out of public prior_art ≤4); Zhang Exendin-4 CA1 blocked by Ex9-39 (promoted); Basalay semaglutide NP abolished by Ex9-39 (promoted); P15 (BPC residual-FBXO22 ≠ Exendin-4×GLP1R residual; P15 ≠ P24); P16 (LKKTETQ-Cc ≠ Exendin-4×GLP1R; P16 ≠ P24); P17 (MOTS-c/folate ≠ Exendin-4×GLP1R; P17 ≠ P24); P18 (SS-31/ROS ≠ Exendin-4×GLP1R; P18 ≠ P24); P19 (ARA290/IRR ≠ Exendin-4×GLP1R; P19 ≠ P24); P20 (Semax/TrkB ≠ Exendin-4×GLP1R; Exendin-4≠Semax; GLP1R≠TrkB; P20 ≠ P24); P21 (Selank/GABA ≠ Exendin-4×GLP1R; Exendin-4≠Selank; GLP1R≠GABA; P21 ≠ P24); P22 (Dihexa/c-Met ≠ Exendin-4×GLP1R; Exendin-4≠Dihexa; GLP1R≠c-Met; P22 ≠ P24); P23 (oxytocin/OXTR ≠ Exendin-4×GLP1R; Exendin-4≠oxytocin; GLP1R≠OXTR; P23 ≠ P24); P1–P23 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P24.card.md card_sha256: 756a60bd168a5e9cb7cb59d702407d6137a5f944883d0714141cba7d8a51c3ad
Mol Labs public report: PENDING dual-publish